Repligen Corp
NASDAQ:RGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Repligen Corp
NASDAQ:RGEN
|
US |
|
Mathew Easow Research Securities Ltd
BSE:511688
|
IN |
|
Gold Standard Ventures Corp
TSX:GSV
|
CA |
|
A
|
Aisino Co Ltd
SSE:600271
|
CN |
|
Scandi Standard AB (publ)
STO:SCST
|
SE |
|
GMO Pepabo Inc
TSE:3633
|
JP |
|
D
|
Dongwon Metal Co Ltd
KRX:018500
|
KR |
|
B
|
Blockchain Group SA
PAR:ALTBG
|
FR |
|
J
|
Jyske Bank A/S
LSE:0MGD
|
DK |
|
Sun* Inc
TSE:4053
|
JP |
|
S
|
San Miguel Corp
OTC:SMGBF
|
PH |
|
Companhia Brasileira de Aluminio
BOVESPA:CBAV3
|
BR |
Repligen Corp
Repligen Corporation has carved a niche for itself in the dynamic world of bioprocessing, a sector that fuels the global production of biologic drugs. At its core, Repligen specializes in providing innovative technologies and solutions that enhance the efficiency and productivity of manufacturing processes for advanced therapeutics, ranging from monoclonal antibodies to cell and gene therapies. The company operates primarily through its product categories, which include filtration, chromatography, and analytics, bridging the gaps in the biomanufacturing process. By focusing on these critical yet underserved areas, Repligen has positioned itself as a pivotal player enabling pharmaceutical and biotech firms to streamline their production lines, reduce costs, and meet the increasing demand for life-saving biologics.
What sets Repligen apart is its strategic approach to generating revenue by staying ahead of industry trends and continuously innovating its product offerings. As biopharmaceutical production shifts towards more personalized and complex therapies, Repligen adeptly supplies the tools and systems required to tackle these challenging demands. The company's revenue model revolves around the sale of its proprietary products, which are essential components in biopharmaceutical manufacturing. By forging strong relationships with industry leaders and consistently delivering high-quality, reliable solutions, Repligen ensures a steady stream of business, leveraging its technological prowess to capture and sustain market share. Through this combination of strategic foresight and steadfast execution, Repligen continues to bolster its reputation as an indispensable ally to the world's leading biotech firms.
Repligen Corporation has carved a niche for itself in the dynamic world of bioprocessing, a sector that fuels the global production of biologic drugs. At its core, Repligen specializes in providing innovative technologies and solutions that enhance the efficiency and productivity of manufacturing processes for advanced therapeutics, ranging from monoclonal antibodies to cell and gene therapies. The company operates primarily through its product categories, which include filtration, chromatography, and analytics, bridging the gaps in the biomanufacturing process. By focusing on these critical yet underserved areas, Repligen has positioned itself as a pivotal player enabling pharmaceutical and biotech firms to streamline their production lines, reduce costs, and meet the increasing demand for life-saving biologics.
What sets Repligen apart is its strategic approach to generating revenue by staying ahead of industry trends and continuously innovating its product offerings. As biopharmaceutical production shifts towards more personalized and complex therapies, Repligen adeptly supplies the tools and systems required to tackle these challenging demands. The company's revenue model revolves around the sale of its proprietary products, which are essential components in biopharmaceutical manufacturing. By forging strong relationships with industry leaders and consistently delivering high-quality, reliable solutions, Repligen ensures a steady stream of business, leveraging its technological prowess to capture and sustain market share. Through this combination of strategic foresight and steadfast execution, Repligen continues to bolster its reputation as an indispensable ally to the world's leading biotech firms.
Revenue Beat: Q4 2025 revenue was $198 million, representing 14% organic growth and exceeding the high end of guidance; full-year revenue reached $738 million.
Growth Momentum: All major franchises saw strong growth, with proteins and analytics up over 30% in Q4, chromatography over 25%, and filtration growing high single digits.
Margin Expansion: Adjusted operating margin expanded to 13.8% for 2025, up 90 basis points, and is guided to expand by another 150 basis points in 2026.
Robust Guidance: 2026 revenue is guided to $810–840 million, or 9–13% organic growth, with analytics expected to grow over 20% and other franchises in the low double digits.
Strong Start Expected: Q1 2026 is expected to be only slightly down from Q4 2025, signaling a strong start to the year despite typical seasonality.
Strategic Priorities: Focus remains on innovation, margin expansion, M&A, cross-selling, and scaling operations, with several new products and services planned for 2026.
China Recovery: China returned to growth in the past two quarters, with strong orders expected to drive further improvements in 2026.
Balanced Outlook: Guidance reflects both strong internal momentum and caution around external factors like FDA approvals and macroeconomic uncertainty.
